Intranasal oxytocin is one of 55 small molecule programs targeting Borderline personality disorder. It is currently in Phase 2.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
332 competitors in Treatment
Intranasal oxytocin
Emtriva
Levulan
Lamprene
Hivid
Foscavir
Valium
Brevibloc
Nerlynx
Clomid
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details